Title: Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series.

Authors: Jones, Lee Ann; Doucette, Lorna; Dellon, Elisabeth P; Esther, Charles R; McKinzie, Cameron J

Published In J Cyst Fibros, (2019 07)

Abstract: Mycobacterium abscessus is a rapidly-growing, virulent, non-tuberculous mycobacterium that causes progressive inflammatory lung damage and significant decline in lung functionin patients with cystic fibrosis. M. abscessus complex pulmonary infections are notoriously difficult to treat, and while many antibiotics are approved for children, drug allergies or intolerances can prohibit their use. Intravenous imipenem/cilastatin is among the preferred antibiotics for treatment of M. abscessus, however, its use may result in systemic toxicities including hepatic injury and gastrointestinal effects. Case reports document the successful use of inhaled imipenem/cilastatin in adult cystic fibrosis and non- cystic fibrosis patients with non- M. abscessus pulmonary infections. To our knowledge, similar evidence does not exist for pediatric patients. In this case series, we describe two pediatric patients with cystic fibrosis and previous intolerance or lack of response to standard therapies who received inhaled imipenem/cilastatin for the treatment of chronic M. abscessus infection.

PubMed ID: 31060800

MeSH Terms: No MeSH terms associated with this publication